Coronavirus Update: J&J Shows Promise Against Omicron, UK Nod For Paxlovid

Plus Comirnaty Touted For Teens

The FDA authorized Comirnaty as a booster shot for 12- to 15-year-olds, as J&J's vaccine has shown effectiveness as a booster in Omicron-dominant settings. Meanwhile, Pfizer's Paxlovid won approval in the UK, and Novavax submitted the final data for its vaccine to the FDA.  

The Sisonke Study Was Conducted By The South African Medical Research Council. • Source: Alamy

Johnson & Johnson’s COVID-19 vaccine booster has demonstrated 85% effectiveness against COVID-19-related hospitalization according to preliminary data from a study by the South African Medical Research Council.

The Phase IIIb Sisonke trial showed the booster shot reduced the risk of hospitalization from COVID-19 in South African healthcare...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip